We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Parallel Tracking i-biomarkerT Development with Drug Development for Maximum Benefit
Video

Parallel Tracking i-biomarkerT Development with Drug Development for Maximum Benefit

Parallel Tracking i-biomarkerT Development with Drug Development for Maximum Benefit
Video

Parallel Tracking i-biomarkerT Development with Drug Development for Maximum Benefit

SELECTBIO
Molecular imaging is increasingly being used to support decision-making in early-stage drug development, particularly in the CNS. Providing invaluable information on the so-called ‘three pillars of drug survival’, namely tissue delivery, target engagement and pharmacological effect, it can be seen as a kind of precision pharmacology However, a lack of appreciation of when and how to use imaging and a lack of suitable tools means imaging is often an afterthought and employed in a post-mortem of drug failure. Timely development of imaging biomarkers will ensure the full translational value of this technology can be realised 
Meet the Author
Kevin Cox
Kevin Cox
Imanova Limited
Advertisement